Morgan Stanley
GNOM icon

Morgan Stanley’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Morgan Stanley’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7K Sell
487
-1
-0.2% -$48 ﹤0.01% 6703
2026
Q1 		$21.3K Buy
488
+1
+0.2% +$46 ﹤0.01% 6701
2025
Q4 		$22.1K Sell
487
-2,048
-81% -$90.8K ﹤0.01% 6663
2025
Q3 		$98.4K Sell
2,535
-1
-0% -$36 ﹤0.01% 6158
2025
Q2 		$85.5K Sell
2,536
-109
-4% -$3.45K ﹤0.01% 6187
2025
Q1 		$84.1K Buy
2,645
+44
+2% +$1.67K ﹤0.01% 6092
2024
Q4 		$101K Sell
2,601
-235
-8% -$9.87K ﹤0.01% 6055
2024
Q3 		$128K Sell
2,836
-464
-14% -$20.7K ﹤0.01% 5903
2024
Q2 		$138K Sell
3,300
-92
-3% -$3.85K ﹤0.01% 5841
2024
Q1 		$154K Buy
3,392
+251
+8% +$11.4K ﹤0.01% 5819
2023
Q4 		$145K Hold
3,141
– – ﹤0.01% 5804
2023
Q3 		$128K Sell
3,141
-75
-2% -$3.42K ﹤0.01% 5768
2023
Q2 		$156K Sell
3,216
-237
-7% -$11.9K ﹤0.01% 5750
2023
Q1 		$170K Buy
3,453
+2,493
+260% +$128K ﹤0.01% 5783
2022
Q4 		$48.6K Sell
960
-1,947
-67% -$100K ﹤0.01% 6303
2022
Q3 		$146K Buy
2,907
+45
+2% +$2.54K ﹤0.01% 5890
2022
Q2 		$140K Hold
2,862
– – ﹤0.01% 6090
2022
Q1 		$172K Sell
2,862
-81
-3% -$5.11K ﹤0.01% 6001
2021
Q4 		$234K Sell
2,943
-110
-4% -$9.24K ﹤0.01% 5983
2021
Q3 		$271K Buy
3,053
+81
+3% +$7.59K ﹤0.01% 5837
2021
Q2 		$296K Sell
2,972
-194
-6% -$17.2K ﹤0.01% 5818
2021
Q1 		$284K Buy
3,166
+2,160
+215% +$213K ﹤0.01% 5461
2020
Q4 		$95K Buy
1,006
+925
+1,142% +$77.4K ﹤0.01% 5931
2020
Q3 		$6K Buy
+81
New +$5.8K ﹤0.01% 6408

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Morgan Stanley's GNOM Position: Q2 2026 in Review

Morgan Stanley reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 0.2% in Q2 2026, selling an estimated $48 and leaving 487 shares worth $27.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6703.

Morgan Stanley first reported a position in GNOM in Q3 2020 and has held it in 24 quarters since. The position peaked at $296K in Q2 2021. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • Morgan Stanley held 487 shares of Global X Genomics & Biotechnology ETF worth $27.7K as of Q2 2026.
  • Morgan Stanley sold 1 Global X Genomics & Biotechnology ETF share in Q2 2026, an estimated $48.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6703 holding.
  • Morgan Stanley first reported a position in Global X Genomics & Biotechnology ETF in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Global X Genomics & Biotechnology ETF position peaked at $296K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.